Selective sodium–glucose cotransporter 2 (SGLT2) inhibitors reduced the risk of hospitalization for heart failure in patients with or without type 2 diabetes (T2DM) in large-scale clinical trials. The exact mechanism of action is currently unclear. The dual SGLT1/2 inhibitor sotagliflozin not only reduced hospitalization for HF in patients with T2DM, but also lowered the risk of myocardial infarction and stroke, suggesting a possible additional benefit related to SGLT1 inhibition. In fact, several preclinical studies suggest that SGLT1 plays an important role in cardiac pathophysiological processes. In this review, our aim is to establish the clinical significance of myocardial SGLT1 inhibition through reviewing basic research studies in th...
Aims\ua0Selective SGLT2 inhibition reduces the risk of worsening heart failure and cardiovascular de...
Abstract Prevention and treatment strategies for heart failure (HF) in diabetes have not been fully ...
Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failu...
Diabetes is a global epidemic and a leading cause of death with more than 422 million patients world...
Abstract Diabetes mellitus currently affects over 350 million patients worldwide and is associated w...
The sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new class of effective drugs managing pa...
Sodium–glucose cotransporter (SGLT)2 inhibitors have been demonstrated to reduce cardiovascular even...
Sodium–glucose cotransporter (SGLT)2 inhibitors have been demonstrated to reduce cardiovascular even...
Sodium-glucose co-transporter 2 (SGLT2) inhibitors have consistently demonstrated improved outcomes ...
Sodium-glucose-cotransporter 2 inhibitors (SGLT2is) demonstrate large cardiovascular benefit in both...
The concurrent management of type 2 diabetes mellitus and heart failure presents several challenges ...
Heart failure (HF) affects up to over 20% of patients with type 2 diabetes (T2DM), even more in the ...
There is growing evidence from Phase III randomized clinical trials of the cardiovascular benefits o...
SGLT2 inhibitors reduce cardiovascular death or hospitalization for heart failure, regardless of the...
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new class of drugs that reduce blood glucose...
Aims\ua0Selective SGLT2 inhibition reduces the risk of worsening heart failure and cardiovascular de...
Abstract Prevention and treatment strategies for heart failure (HF) in diabetes have not been fully ...
Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failu...
Diabetes is a global epidemic and a leading cause of death with more than 422 million patients world...
Abstract Diabetes mellitus currently affects over 350 million patients worldwide and is associated w...
The sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new class of effective drugs managing pa...
Sodium–glucose cotransporter (SGLT)2 inhibitors have been demonstrated to reduce cardiovascular even...
Sodium–glucose cotransporter (SGLT)2 inhibitors have been demonstrated to reduce cardiovascular even...
Sodium-glucose co-transporter 2 (SGLT2) inhibitors have consistently demonstrated improved outcomes ...
Sodium-glucose-cotransporter 2 inhibitors (SGLT2is) demonstrate large cardiovascular benefit in both...
The concurrent management of type 2 diabetes mellitus and heart failure presents several challenges ...
Heart failure (HF) affects up to over 20% of patients with type 2 diabetes (T2DM), even more in the ...
There is growing evidence from Phase III randomized clinical trials of the cardiovascular benefits o...
SGLT2 inhibitors reduce cardiovascular death or hospitalization for heart failure, regardless of the...
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new class of drugs that reduce blood glucose...
Aims\ua0Selective SGLT2 inhibition reduces the risk of worsening heart failure and cardiovascular de...
Abstract Prevention and treatment strategies for heart failure (HF) in diabetes have not been fully ...
Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failu...